Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2022-04-04 Capital/Financing Update
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Pharnext: Tirage d'une neuvième tranche de 300 obligations convertibles en actions
Capital/Financing Update Classification · 1% confidence The document is a press release dated April 4, 2022, announcing the drawing down of a ninth tranche of convertible bonds (OCA) from a financing agreement (OCEANE-BSA). The text explicitly details the terms of financing, the use of proceeds (funding clinical trials), and references prior shareholder authorizations for the issuance program. This content directly relates to the company's fundraising and capital structure activities. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). The document is a formal announcement, not a comprehensive annual or interim report, nor is it a transcript or a proxy statement.
2022-04-04 French
Joshua Schafer est nommé Président par intérim du Conseil d'Administration de Pharnext
Board/Management Information Classification · 1% confidence The document is a press release dated March 30, 2022, announcing a significant change in corporate governance: the appointment of Joshua Schafer as Interim Chairman of the Board of Directors following the resignation of Elisabeth Svanberg. This content directly relates to changes in the company's board of directors and senior management structure. According to the definitions, this aligns perfectly with the 'Board/Management Information' category (Code: MANG). The document is not a formal regulatory filing like a 10-K, an earnings release, or a dividend notice; it is a specific announcement about management personnel.
2022-03-30 French
Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
Board/Management Information Classification · 1% confidence The document is a press release announcing a change in senior leadership: Joshua Schafer has been appointed as the Interim Chairman of the Board of Directors, following the resignation of the previous Chairperson. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-03-30 English
Pharnext: Tirage d'une huitième tranche de 300 obligations convertibles en actions
Capital/Financing Update Classification · 1% confidence The document is a press release dated March 15, 2022, announcing the drawing down of an eighth tranche of convertible bonds (OCA) from an investor (Global Tech Opportunities 13). This action involves raising capital through debt instruments that can convert into equity, specifically mentioning the use of funds for clinical trials (PREMIER study) and referencing prior financing agreements and shareholder authorizations for capital increases. This activity directly relates to the company's fundraising, financing activities, and capital structure changes. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2022-03-15 French
Pharnext: Assemblée Générale Extraordinaire fixée au 21 mars 2022
AGM Information Classification · 1% confidence The document explicitly discusses an "Assemblée Générale Extraordinaire" (Extraordinary General Meeting) scheduled for March 21, 2022. It details procedural matters related to shareholder voting, quorum requirements, and the appointment of a *mandataire ad hoc* (legal representative for absent shareholders). This content directly relates to the formal proceedings and materials associated with a shareholder meeting. The most fitting category is AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (or Extraordinary General Meeting, as the context implies a shareholder meeting). Although it mentions the notice will be published in BALO (a regulatory filing), the core content is about the meeting itself, not just the announcement of the meeting.
2022-03-08 French
Pharnext: Report de l'assemblée générale extraordinaire des actionnaires du 28 février 2022
AGM Information Classification · 1% confidence The document is explicitly titled "Report de l'assemblée générale extraordinaire des actionnaires du 28 février 2022" (Report of the Extraordinary General Meeting of Shareholders of February 28, 2022). It discusses the failure to meet the quorum required for the meeting to proceed and the subsequent decision to postpone it. This content directly relates to the proceedings and materials of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length is short (3177 chars), but it is the report/update *about* the meeting itself, not just an announcement that a report will follow, making AGM-R more specific than RPA or RNS.
2022-02-28 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.